جست‌وجوی استاد و پژوهشگر

Paul Millerمشاهده پروفایل

پژوهشگر

• Molecular Pharmacology
• Structural Biology
• Neuropharmacology
• +۷ مورد دیگر

Paul Miller is a researcher in the Department of Pharmacology at the University of Cambridge, part of the School of Biological Sciences. His work focuses on the structural and molecular pharmacology of ligand-gated ion channels, particularly GABAA and glycine receptors, with a strong emphasis on allosteric modulation and receptor activation mechanisms. His research interests lie at the intersection of structural biology, neuropharmacology, and molecular biophysics. He investigates how neurosteroids, zinc, and other modulators influence receptor function, using structural and biochemical approaches to uncover mechanisms of drug action. His work contributes to understanding inhibitory neurotransmission and developing targeted CNS therapeutics. The publication record shows a consistent focus on Cys-loop receptors, especially GABA and glycine receptors, with recent work advancing structural insights into receptor activation and drug selectivity. Themes include receptor subtype specificity, allosteric modulation, metal ion effects, and high-resolution structural determination via cryo-EM and crystallography. While no formal awards are listed in the provided text, his contributions to the field are evident through high-impact publications in structural pharmacology. Paul Miller advises postgraduate researchers and contributes to the academic mission of the Department of Pharmacology. His work is supported by research grants in molecular neuroscience and structural pharmacology, though specific funding sources are not detailed. He is an active member of the department’s research and postgraduate education committees. He is involved in research groups focusing on receptor biology and the Naked Mole-Rat Initiative, contributing to innovative models in pharmacological research.

Fabian Barthelsمشاهده پروفایل

پژوهشگر

• RNA Biology
• Medicinal Chemistry
• Epitranscriptomics
• +۶ مورد دیگر

Dr. Fabian Barthels is a Researcher and Research Group Leader at the Institute of Pharmaceutical and Biomedical Sciences of Johannes Gutenberg-Universität Mainz , Germany. His work focuses on RNA methyltransferases, epitranscriptomics, and medicinal chemistry technologies. Ph.D. in Medicinal Chemistry (University of Mainz, 2018) Biochemistry M.Sc. (University of Tübingen, 2016) Biochemistry B.Sc. (University of Tübingen, 2013–2016) Dr. Barthels' research explores dysregulation of RNA modifications in disease pathology, developing selective covalent/non-covalent inhibitors for RNA methyltransferases using DNA-encoded libraries and PROTACs. His group created microscale thermophoresis assays and 3D-printed lab equipment like FINDUS and a differential scanning fluorometer. His group's publications highlight advancements in RNA-MST protocols, METTL1/DNMT2 inhibitor discovery, and photoaffinity probes for viral proteases. Recent work includes fluorescent MTase probes (Angewandte Chemie 2024) and RNA-ligand interaction studies (Chemical Science 2023). 2023 Boehringer-Ingelheim Foundation Dissertation Award 2022 Walter-Schunack Prize in Medicinal Chemistry 2022 Phoenix Pharmacy Award (co-awarded) 2016–2018 Deutschlandstipendium for academic potential Dr. Barthels' lab includes researchers like Ariane Frey (Poster Award winner) and Annabelle Weldert (best presentation awardee). His DFG-funded Transregio 319 project on RNA Modification and Processing and CZS MAINCE initiative on Medical AI demonstrate his grant leadership.

Erik Lindahlمشاهده پروفایل

استاد

• Membrane Proteins
• Ion Channels
• Molecular Dynamics
• +۵ مورد دیگر

Erik Lindahl is a Professor at Stockholm University with a co-affiliation at KTH Royal Institute of Technology. He leads a research group at SciLifeLab focused on membrane proteins, particularly ion channels and pumps that transport ions for nervous system functioning. His work bridges computational and experimental approaches in biophysics. Dr. Lindahl's research spans multiple disciplines within biophysics and computational biology. His team uses bioinformatics to build models of human receptors based on bacterial structures, biomolecular simulations to understand molecular-level interactions, and experimental techniques like electrophysiology and spectroscopy. Key research areas include voltage-gated ion channels, ligand-gated ion channels, ATPase pumps, and allosteric modulation. His group has made significant contributions to understanding how these molecular machines function at the atomic level. The recent publications reveal a strong focus on the structural and functional mechanisms of ion channels and membrane proteins. His work combines molecular dynamics simulations with experimental validation, particularly in the areas of voltage sensing, alcohol modulation of receptors, and ion pump mechanisms. The publications demonstrate expertise in both computational methodology development and biological application. Dr. Lindahl leads a substantial research group with multiple PhD students, postdocs, and researchers. His team collaborates extensively, as evidenced by the multi-institutional authorship on his publications. He also contributes to major methodological developments in computational biophysics, most notably through his involvement with the GROMACS molecular simulation package. The research group operates at the intersection of several laboratories and facilities, leveraging both computational resources and experimental setups for electrophysiology and structural biology. This integrated approach allows the team to tackle complex questions about membrane protein function from multiple angles, combining theoretical modeling with empirical validation.

Marc Nazaréمشاهده پروفایل

استاد

• Medicinal Chemistry
• Chemical Biology
• Drug Discovery
• +۳ مورد دیگر

Prof. Dr. Marc Nazaré leads the Nazaré Group at the Leibniz Research Institute for Molecular Pharmacology (FMP) in Berlin and holds a honorary professorship at the University of Bielefeld. His research focuses on designing chemical probes and imaging tools to study biological processes, with emphasis on modulating protein interactions and developing fluorescent sensors for biomedical applications. He has extensive industry experience, including roles at Sanofi and collaborations with pharmaceutical companies like AstraZeneca and Roche. Education: PhD in Organic Chemistry (University of Karlsruhe, 1999) Affiliations: FMP (since 2013), EU-OPENSCREEN partner Key Projects: Development of MAGL imaging probes, fluorescent chemical sensors, and targeted protein degradation tools His group has produced over 20 patents, including work on P2Y12 antagonists, tankyrase inhibitors, and novel probe scaffolds. Collaborations span academia and industry, with a focus on translational applications in drug discovery and diagnostics.

Lauren Mayمشاهده پروفایل

مدرس ارشد

• Drug Discovery
• Pharmacology
• GPCR Signaling
• +۴ مورد دیگر

Lauren May is a Senior Lecturer and Group Leader in the Department of Drug Discovery Biology at the Monash Institute of Pharmaceutical Sciences, which is part of the Faculty of Pharmacy and Pharmaceutical Sciences at Monash University. Her research focuses on G protein-coupled receptors (GPCRs), with an emphasis on their roles in cardiovascular diseases, neurological disorders, and drug discovery. Key areas include adenosine receptor pharmacology, biased agonism, and the development of novel therapeutics targeting GPCRs for conditions such as heart failure and epilepsy. May has led and contributed to numerous research projects, including the development of adenosine A1 receptor modulators for epilepsy treatment and formyl peptide receptor agonists for myocardial infarction. She is also actively involved in advancing drug discovery methodologies, such as AI-driven approaches for molecular property prediction and drug-target interaction modeling. Her work contributes to UN Sustainable Development Goals related to good health and well-being (SDG 3), particularly through innovative therapeutic strategies. In addition to her research, May holds editorial roles in journals like British Journal of Pharmacology and Purinergic Signalling , demonstrating her leadership in the field. Her projects often involve interdisciplinary collaborations, bridging basic science with translational medicine to address unmet clinical needs.

Sandhya Kortagereمشاهده پروفایل

استاد

• Neurodegenerative Diseases
• Pharmacology
• Molecular Biology
• +۵ مورد دیگر

Sandhya Kortagere, PhD, is a Professor in the Department of Microbiology & Immunology at Drexel University College of Medicine. She earned her PhD in Molecular Pharmacology from the National Institute of Mental Health and Neurosciences, India (2003). Her research focuses on developing small-molecule therapeutics for neurodegenerative diseases, particularly Parkinson’s disease (PD), targeting dopamine receptors and catecholamine transporters. Her work includes designing biased signaling agonists to mitigate Levodopa-induced dyskinesia (LID) and impulsive/compulsive behaviors, as well as allosteric modulators of monoamine transporters to block psychostimulant effects. Her research also addresses PD-related non-motor symptoms like mild cognitive impairment, leveraging compounds like SK609. Additionally, she explores neuroinflammation and excitotoxicity pathways in PD, developing neuroprotective agents like KA592 and GT951. In infectious diseases, her lab designs antimalarials targeting Plasmodium falciparum protein interactions, with compounds licensed to Medicines for Malaria Venture (MMV). Key Projects: Biased D3R agonists for LID, dopamine/norepinephrine modulators for cognitive deficits, and allosteric modulators of DAT/SERT. Commercialization: Founded PolyCore Therapeutics to advance PCT-3010 (SK609) into clinical trials for PD. Awards include the Drexel Institutional Service Award (2024) and Provost Solutions Fellowship (2022-23). Her lab collaborates with researchers like Dr. Ole Mortensen and Dr. Jim Harris (PolyCore CEO), advancing translational drug development.

• Biophysics of Proteins
• Enzyme Mechanisms
• Industrial Biotechnology
• +۳ مورد دیگر

Dr. Sharon Williams is a Lecturer in Biomedical Science at Coventry University’s School of Life Sciences, part of the Faculty of Health and Life Sciences. She holds a PhD in Biochemistry and previously worked as a postdoctoral research fellow at the University of Warwick between 2002 and 2010, focusing on protein biophysics, enzyme mechanisms, and molecular biology. Her current research emphasizes industrial biotechnology applications, particularly lignin degradation for biofuel production and the twin-arginine translocation (Tat) pathway’s role in protein transport and drug development. Education: PhD in Biochemistry Associate Fellow of the Higher Education Academy (HEA) PgCert qualification Member of the Royal Society of Chemistry Research Interests: Dr. Williams’ work spans enzymology, protein transport mechanisms, and biocatalytic applications. Key areas include: Engineering enzymes for lignin degradation to produce high-value aromatic chemicals Exploiting the Tat pathway for therapeutic protein production and drug target development Investigating the phenylpropionate catabolic pathway in E. coli Her research bridges fundamental biology with industrial innovation, particularly in sustainable bioresource utilization. Teaching Contributions: She teaches modules in biomolecular sciences, analytical chemistry, and forensic science, including advanced coursework in molecular genetics and research design. Recognition: While no formal awards are listed, her active membership in the Royal Society of Chemistry underscores her professional engagement. Ongoing projects focus on lignin-derived bio-products and Tat pathway applications in biotechnology. Labs/Teams: Collaborates within Coventry University’s Life Sciences research groups, though specific lab names are not detailed in the provided text.

Amy Andreottiمشاهده پروفایل

استاد

• Nuclear Magnetic Resonance
• Macromolecular Structure and Recognition
• Protein Kinases
• +۷ مورد دیگر

Amy Andreotti holds the Roy J. Carver Chair and serves as a University Professor in the Department of Biochemistry, Biophysics, and Molecular Biology at Iowa State University. Her research focuses on structural and regulatory mechanisms of Tec family kinases like ITK and BTK, using nuclear magnetic resonance (NMR) and biochemical approaches to investigate immune signaling pathways and disease-related dysregulation. Amy Andreotti’s educational background includes: A.B. in Chemistry and Studio Art from Bowdoin College (1989) Ph.D. in Chemistry from Princeton University (1994) Postdoctoral Fellowship at Harvard University (1994–1997) Research Interests: Her work explores how structural features of Tec kinases govern their activity, with a focus on proline isomerization, interdomain interactions, and phospholipid binding. She studies these kinases’ roles in T-cell and B-cell signaling and develops targeted inhibitors to modulate their activity in diseases like chronic lymphocytic leukemia. NMR spectroscopy and structural biology are central to her methods, enabling detailed analysis of kinase conformational dynamics and substrate recognition. Publications Trends: Recent work emphasizes BTK’s clinical inhibitors and resistance mechanisms in cancer, alongside structural studies of Tec kinases. Earlier research highlighted ITK’s regulation by cyclophilin A and calmodulin, and the role of SH3-SH2 domain interactions in kinase activation. Her studies often integrate biochemical, structural, and computational methods to bridge basic and translational research. Roy J. Carver Chair (Endowed Professorship) Advising & Grants: No formal advisees are listed. While specific grants aren’t detailed, her research likely involves funding for drug development and structural biology projects. She collaborates with pharmaceutical researchers and biotechnology groups to advance therapeutic strategies targeting kinase dysfunction. Labs & Teams: Her research is conducted within the facilities of Iowa State University’s Roy J. Carver Department, leveraging resources like the Office of Biotechnology and MBB Conference Rooms. She participates in interdisciplinary initiatives such as the Stupka Research Symposium and Graduate Learning Community to foster collaborative research in structural biology and pharmacology.

• Behavioral Pharmacology
• Epilepsy Research
• Neuropharmacology
• +۶ مورد دیگر

Dr. Misty Smith is a Research Associate Professor at the University of Utah's School of Dentistry and holds a joint appointment in the Department of Pharmacology and Toxicology. Her research focuses on epilepsy and antiseizure drug development, particularly investigating cannabidiol interactions, behavioral comorbidities of epilepsy, and neuropeptide roles in neurological conditions. She leads NIH-funded studies in the Anticonvulsant Drug Development Program, ensuring regulatory standards and preclinical model rigor. Dr. Smith's work emphasizes therapeutic potential evaluation using isobolographic analysis and pharmacokinetic studies. Educations: BS in Biology, Muskingum University, 1996 PhD in Physiology, University of South Carolina School of Medicine, 2001 Research Interests: Dr. Smith's research integrates behavioral pharmacology with preclinical epilepsy models to address comorbidities like neuropsychiatric conditions. She explores cannabidiol's efficacy in combination therapies and investigates neuropeptide systems (e.g., neurotensin, galanin) and steroid hormones' roles in seizure modulation. Her work highlights sex differences in neurological responses and drug interactions to improve treatment safety and efficacy. Key Awards: Targeted Research Initiative for Cannabidiol in Epilepsy (TRICE) Award (2015) Distinguished Doctorate Alumni Award (2013) Elected Member-At-Large of ASPET's Neuropharmacology Division (2012) Grants & Funding: Isobolographic Analyses of Cannabidiol Interactions with Antiseizure Drugs (Epilepsy Foundation, 2014–2016) Multiple grants focused on epilepsy drug screening and cannabidiol's mechanisms Labs & Teams: Core member of the NIH-sponsored Anticonvulsant Drug Development (ADD) Program, coordinating preclinical research and regulatory compliance.

Pierre Lafayeمشاهده پروفایل

پژوهشگر

• Antibody Engineering
• Nanobodies (VHH)
• Immunotherapy
• +۱۳ مورد دیگر

Pierre Lafaye is the Head of the Antibody Engineering Platform at the Institut Pasteur, a leading institution in biological and medical research. His work is situated within the Technology Department, where he leads a core facility focused on the development and application of VHH (nanobody) technologies. The platform supports a wide range of academic and translational research projects, leveraging the unique properties of nanobodies such as small size, high stability, tissue penetration, and blood-brain barrier crossing ability. Research Interests: Dr. Lafaye’s research spans multiple domains, including cancer immunotherapy (e.g., targeting ILT4 as an immune checkpoint), neurodegenerative diseases (e.g., imaging Alzheimer’s plaques and tangles), infectious diseases (e.g., SARS-CoV-2 diagnostics and therapeutics), and antimicrobial resistance (e.g., targeting β-lactamases). His expertise lies in phage display, protein engineering, and in vivo molecular imaging. He has pioneered the use of dimeric VHHs for sensitive immunoassays and targeted diagnostics. Recent Publication Trends: His recent publications (2021–2024) reflect a strong emphasis on structural biology (using cryo-EM), viral entry mechanisms (especially coronaviruses), and the therapeutic and diagnostic application of nanobodies. Collaborative, high-impact studies in journals like Nature , Cell , and Nature Communications highlight his role in cutting-edge interdisciplinary research. Scientific Awards: While no specific awards are listed in the provided text, his leadership in IBiSA-certified core facilities and participation in major networks like EuroMabNet, Core For Life (CFL), and CTLS reflect recognition of his technical and scientific contributions. Advising and Grants: Dr. Lafaye has supervised multiple PhD students and postdoctoral researchers, indicating an active mentoring role. He leads several funded projects, including the ongoing CORONABODIES and Advances in Cancer Immunotherapy projects, as well as completed initiatives like ChagasDiag and VenoMATIcs. These projects involve collaborations across international Pasteur Institutes and academic partners. Labs and Teams: As head of the Antibody Engineering Platform, he oversees a multidisciplinary team comprising research engineers, technicians, postdocs, and PhD students. The facility is part of broader transversal initiatives at the Institut Pasteur, including those in brain connectivity, cancer, and emerging infectious diseases.

Celine Valantمشاهده پروفایل

دانشیار

• GPCRs
• Allostery
• Muscarinic Receptor
• +۳ مورد دیگر

Celine Valant is an Associate Professor (Research) in Drug Discovery Biology at Monash University's Faculty of Pharmacy and Pharmaceutical Sciences. She holds a concurrent Post-doctoral Fellow position within the Monash Institute of Pharmaceutical Sciences. Her research focuses on muscarinic acetylcholine receptors (mAChRs), GPCRs, and allostery, with applications to neurocognitive disorders, schizophrenia treatment, and gastrointestinal motility disorders. Valant has led multiple projects including investigations into M4 muscarinic receptor modulation for schizophrenia (2023-2026) and endogenous opioids for gut disorders (2023-2026). She has published extensively in journals like Journal of Medicinal Chemistry and British Journal of Pharmacology , with recent work emphasizing biased agonism, allosteric modulator design, and receptor structural biology. Her awards include the 2015 Citation Award and 2012 Denis Wade Johnson & Johnson New Investigator Award. Valant has reviewed for ACS Chemical Biology and organized events like the 2018 MP-GPCR conference. Current research themes include M1/M4 receptor therapeutic potential, ligand-directed signaling, and GPCR structural dynamics.

Molinari Maurizioمشاهده پروفایل

پژوهشگر

• Protein Folding
• Proteostasis
• Endoplasmic Reticulum Quality Control
• +۴ مورد دیگر

Maurizio Molinari is a Group Leader at the Institute for Research in Biomedicine (IRB) in Bellinzona, Switzerland, since October 2000. He earned his PhD in Biochemistry from ETH-Zurich in 1995 and conducted postdoctoral research at the University of Padua and ETH-Zurich. His work focuses on protein folding, quality control, and degradation mechanisms within the endoplasmic reticulum (ER), with implications for rare diseases and Alzheimer’s pathology. Affiliation: IRB Bellinzona, Adjunct Professor at EPFL since 2008 Education: PhD in Biochemistry (ETH-Zurich, 1995) Dr. Molinari’s research explores the ER-phagy pathway , proteostasis , and lysosomal degradation as failsafe mechanisms during ER stress. His studies link these processes to neurodegenerative diseases , myelin maintenance , and rare genetic disorders . Recent publications highlight his contributions to allosteric enzyme modulation , organelle fragmentation , and computational tools for autophagy quantification . He received the Friedrich-Miescher Award in 2006 for his work in molecular biology. Scientific Networks: European Research Council (ERC), Rare Diseases Platform (Switzerland) Leadership Roles: Advisory Board, Centro Malattie Rare della Svizzera italiana

• Membrane Proteins
• Ion Channels
• Biophysics
• +۳ مورد دیگر

Ana Marcela serves as an Assistant Professor in the Department of Agrochemistry and Environment at Miguel Hernández University of Elche, Spain. She conducts research within the Structure-function relationships in membrane proteins group at the Ion Channels: Structure & Function Laboratory (Lab 2.9), focusing on biophysical characterization of membrane proteins and ion channels. Her research spans Membrane Proteins, Ion Channels, Biophysics, Biochemistry, Lipid-Protein Interactions, and Structural Biology. She employs advanced fluorescence methodologies including homo-FRET, time-resolved spectroscopy, and equilibrium binding studies to investigate conformational dynamics in potassium channels (particularly KcsA), lipid modulation of channel function, and intrinsically disordered proteins like NUPR1 and PADI4. Her work bridges fundamental biophysics with cancer biology through studies of lipid-enzyme interactions. Analysis of her 2021-2025 publications reveals consistent focus on ion channel dynamics, with particular emphasis on selectivity filter mechanisms, gating cycles, and lipid-protein interactions. Key themes include pH-induced conformational changes in potassium channels, anionic phospholipid effects on channel inactivation, and biophysical characterization of cancer-related enzymes like PADI4 using structural and biochemical approaches. No scientific awards were mentioned in the provided information. No information regarding student advisees or research grants was provided in the source material, though her active teaching role in pharmacy programs indicates ongoing academic supervision responsibilities. She maintains active research operations within the Ion Channels: Structure & Function Laboratory (Lab 2.9), collaborating with the Structure-function relationships in membrane proteins research group while utilizing specialized fluorescence methodologies for membrane protein characterization.

• Biochemistry
• Protein Science
• Pharmaceutical Chemistry
• +۲ مورد دیگر

Stefano Bruno is an Associate Professor at the Department of Pharmacy, University of Parma with a focus on Biochemistry . He holds a PhD in Biochemical Sciences from the University of Turin (2002) and has been teaching since 2004, including courses like Applied Biochemistry and Clinical Biochemical Analysis across multiple degree programs. Education : 1997: MS in Pharmaceutical Chemistry, University of Parma 2002: PhD in Biochemical Sciences, University of Turin His research spans heme proteins , enzyme characterization , and pharmaceutical applications . Key areas include: Structural and functional analysis of hemoproteins (e.g., neuroglobin, cytoglobin) Development of blood substitutes via hemoglobin modifications Investigation of serine racemase and phosphoserine phosphatase in neurological contexts Protein immobilization in silica gels for functional studies His publications (70+ peer-reviewed, H-index 20) emphasize Antarctic bacterial proteins , enzymatic inhibition , and radiopharmaceutical quality control . He has supervised 8 PhD students and contributed to international conferences like the International Symposium on Blood Substitutes . Recent work includes fluorescent biosensors, NO sensing proteins, and covalent enzyme inhibitors for cancer therapy . Awards : No specific scientific awards listed. Teaching & Leadership : Active in PhD programs ( Biochemistry , Pharmaceutical Sciences ), international schools like the ULLA Summer School , and conference organization (e.g., New Challenges in Protein Science ).

Kevin Frankowskiمشاهده پروفایل

استادیار

• Medicinal Chemistry
• Synthetic Chemistry
• Cancer Biology
• +۷ مورد دیگر

Kevin Frankowski, PhD, is an American Assistant Professor at the UNC School of Medicine and member of the UNC Lineberger Comprehensive Cancer Center . His research spans Medicinal Chemistry , Cancer Biology , and Neurotransmitter Signaling , focusing on developing small molecule tools for unmet medical needs. University : University of North Carolina at Chapel Hill Academic Rank : Assistant Professor Department : Molecular Therapeutics Area of Interest Research emphasizes metastatic cancer and CNS signaling , with key projects including: Antimetastatic agent metarrestin (in phase I trials for solid tumors) Dopamine/sigma receptor modulators for neurological disorders Natural product-inspired chemical synthesis for novel scaffolds Electrochemical oxidation methods for drug discovery Scientific awards include IBM/RJ Reynolds Faculty Development Award and multiple national poster prizes. Lab team members include Christiana Nnabuife, Feijun Wang, and Amber Kelley (now Assistant Professor at North Park University). Recent publications focus on dopamine receptor modulation and electrochemical synthesis in journals like JMC and Advanced Synthesis & Catalysis .